A study performed by scientists in Korea has demonstrated that women who go through surgical menopause undergo poorer sleep quality. Additionally, they are also at an elevated threat of insomnia than women who experience the menopause naturally.
Among the ordinary signs of menopause is insomnia and disrupted sleep is reported by nearly one-quarter of the post-menopausal females. In surgical menopause cases, females often experience more physical and psychological issues than females who undergo the menopause naturally.
The signs of menopause such as night sweats and hot flashes are more intense during a time in the life of a woman where disrupted sleep is an issue already. Nevertheless, only some quantitative studies have examined sleep-disrupting patterns among postmenopausal women.
In the existing research, scientists have compared these conducts dependent on whether a female had undergone a natural or surgical menopause. As the study’s part, over 500 post-menopausal women finished questionnaires developed to evaluate the quality of sleep.
As reported in The North American Menopause Society journal, Menopause, the results demonstrated that females who had gone through surgical menopause reported considerably poorer sleep quality compared to those who had experienced the menopause naturally, principally for habitual sleep efficiency and sleep duration.
The research also demonstrated that females in the surgical menopause group were at over twofold the risk of experiencing insomnia. Additionally, females who had gone through surgical menopause who showed more sleep-disrupting patterns had more intense insomnia signs.
On the other end, the U.S. Food and Drug Administration, a few days back, granted commercialization of the PicoAMH Elisa diagnostic test to assist in verifying menopausal status of women to Ansh Labs, a manufacturer and developer of immunoassay reagent test kits utilized to advance therapeutic development, target discovery, clinical diagnostics, and biomedical research. Its picoAMH, Anti-Müllerian (AMH) assay kit, will be marketed by the firm under the trademark MenoCheck™.